Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 39Radiotherapy 18Lomustine 12Bevacizumab 11Carmustine 8Radiation 7Procarbazine 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3pembrolizumab 2depatuxizumab mafodotin 2Tf-CRM107 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Drug Therapy 2Dihematoporphyrin Ether 2DNA Methylation 2Carboplatin 2ABT-414 2trans-sodium crocetinate 1tofacitinib 1sargramostim 1rindopepimut 1niraparib 1marizomib 1enzastaurin 1edotecarin 1contrast agent BR1 1cediranib 1carmustine, poliferprosan 20 drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Glioblastoma × Semustine × Clear all
NCT00335075 2017-05-15

Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)

Merck Sharp & Dohme LLC

Phase 3 Completed
151 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡